Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Research Study to Evaluate BLX-7006 in Healthy Adults
Sponsor: Biolexis Therapeutics
Summary
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.
Official title: A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) BLX-7006 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg/m2
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2025-09
Completion Date
2026-05
Last Updated
2025-08-24
Healthy Volunteers
Yes
Interventions
BLX-7006
BLX-7006 Single or Multiple doses administered orally as a tablet
Placebo
Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.
Locations (1)
Nucleus Network Brisbane Clinic
Brisbane, Queensland, Australia